Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Quaternary ammonium salts (QAS) are irreplaceable membrane-active antimicrobial agents that have been widely used for nearly a century. Cetylpyridinium chloride (CPC) is one of the most potent QAS. However, recent data from the literature indicate that CPC activity against resistant bacterial strains is decreasing. The major QAS resistance pathway involves the QacR dimer, which regulates efflux pump expression. A plausible approach to address this issue is to structurally modify the CPC structure by adding other biologically active functional groups. Here, a series of QAS based on pyridine-4-aldoxime were synthesized, characterized, and tested for antimicrobial activity in vitro. Although we obtained several potent antiviral candidates, these candidates had lower antibacterial activity than CPC and were not toxic to human cell lines. We found that the addition of an oxime group to the pyridine backbone resulted in derivatives with large topological polar surfaces and with unfavorable cLog P values. Investigation of the antibacterial mode of action, involving the cell membrane, revealed altered cell morphologies in terms of corrugated and/or disrupted surface, while 87% of the cells studied exhibited a permeabilized membrane after 3 h of treatment at 4 × minimum inhibitory concentration (MIC). Molecular dynamic (MD) simulations of the interaction of QacR with a representative candidate showed rapid dimer disruption, whereas this was not observed for QacR and QacR bound to the structural analog CPC. This might explain the lower bioactivity of our compounds, as they are likely to cause premature expression of efflux pumps and thus activation of resistance.

Details

Title
New Membrane Active Antibacterial and Antiviral Amphiphiles Derived from Heterocyclic Backbone of Pyridinium-4-Aldoxime
Author
Crnčević, Doris 1 ; Krce, Lucija 2   VIAFID ORCID Logo  ; Cvitković, Mislav 2   VIAFID ORCID Logo  ; Brkljača, Zlatko 3 ; Sabljić, Antonio 1 ; Vuko, Elma 4   VIAFID ORCID Logo  ; Primožič, Ines 5 ; Odžak, Renata 6   VIAFID ORCID Logo  ; Šprung, Matilda 6   VIAFID ORCID Logo 

 Department of Chemistry, Faculty of Science, University of Split, R. Bošković 33, 21 000 Split, Croatia; [email protected] (D.C.); [email protected] (A.S.); Doctoral Study of Biophysics, Faculty of Science, University of Split, R. Bošković 33, 21 000 Split, Croatia 
 Department of Physics, Faculty of Science, University of Split, R. Bošković 33, 21 000 Split, Croatia; [email protected] (L.K.); [email protected] (M.C.) 
 Division of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Bijenička c. 54, 10 000 Zagreb, Croatia; [email protected]; Selvita Ltd., Prilaz Baruna Filipovića 29, 10 000 Zagreb, Croatia 
 Department of Biology, Faculty of Science, University of Split, R. Bošković 33, 21 000 Split, Croatia; [email protected] 
 Department of Chemistry, Faculty of Science, University of Zagreb, Horvatovac 102a, 10 000 Zagreb, Croatia; [email protected] 
 Department of Chemistry, Faculty of Science, University of Split, R. Bošković 33, 21 000 Split, Croatia; [email protected] (D.C.); [email protected] (A.S.) 
First page
775
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
14248247
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2694019696
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.